Instrumenti kvaliteta života specifični za dermatologiju, sve češće se primenjuju u istraživanju kod pacijenata sa kožnim bolestima. CIlj je ispitati odnos ocena kvaliteta života dobijenih primenom dva za dermatologiju specifična instrumenta. Istraživanjem je obuhvaćeno 62 ispitanika sa kožnim bolestima, kod kojih je kvalitet života ocenjen primenom instrumenata specifičnih za dermatologiju (tj. Dermatology Life Quality Index-DLQI i Skindex-16), namenjenih upotrebi kod svih kožnih bolesti. Ukupni skorovi DLQI i Skindex-16 nalazili su se u jakoj korelaciji (r=0.87; p<0.001). Postojale su i statistički značajne korelacije ukupnog skora DLQI sa skorovima za podskale simptomi, emocije i funkcionisanje iz Skindex-16 instrumenta (r=0.53, r=0.77 i r=0.86, redom). Ukupan skor Skindex-16 nije bio u korelaciji sa skorom za podskalu tretman iz DLQI-a, međutim, bio je u korelaciji sa skorovima za podskale simptomi i osećanja, dnevne aktivnosti, slobodne aktivnosti, rad ili škola i lični odnosi iz DLQI-a (r=0.67, r=0.80, r=0.66, r=0.62 i r=0.68, redom). Dva instrumenta specifična za dermatologiju (npr. DLQI i Skindex-16), ukoliko se zajedno primenjuju, mogu pružiti komplementarne podatke pri ocenjivanju kvaliteta života pacijenata sa kožnim bolestima.
Boehm D, Schmid-Ott G, Finkeldey F, John S, Dwinger C, Werfel T, et al. Anxiety, depression and impaired health-related quality of life in patients with occupational hand eczema. Contact Dermatitis. 2012;(4):184–92.
2.
Timotijević S, Janković Z, Trajković S, Majcan G, Perišić P, Dostanić S, et al. Identification of psoriatic patients at risk of high quality of life impairment. J Dermatology. 2013;797–804.
3.
Krishna G, Ramam M, Mehta M, Sreenivas V, Sharma V, Khandpur V. Vitiligo impact scale: An instrument to assess the psychosocial burden of vitiligo. Indian Journal of Dermatology Venereology, and Leprology. 2013;(2):205–10.
4.
Abolfotouh M, Ms AK, Suliman W, Da AT, Bluwi A, E, et al. Quality of life in patients with skin diseases in central Saudi Arabia. Int J Gen Med. 2012;633–42.
5.
Peuvrel L, Quereux G, Brocard A, Saint-Jean M, Vallet C, Mere A, et al. Evaluation of quality of life after a medical corrective make-up lession in patients with various dermatoses. Dermatology. 2012;(4):374–80.
6.
Sampogna F, Tabolli S, Abeni D, Idi. Multipurpose Psoriasis Research on Vital Experiences (IMPROVE) investigators. Living with psoriasis: prevalence of schame, anger, worry, and problems in daily activites and social life. Acta Derm Venereol. 2012;299–300.
7.
Shikiar R, Willian M, Okun M, Thompson C, Revicki D. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes. 2006;71.
8.
Chren M. The Skindex instruments to measure the effects of skin disease on quality of life. Dermatol Clin. 2012;(2):231–6.
9.
Zachariae R, Zachariae C, Ibsen H, Mortensen J, Wulf H. Dermatology Life Quality Index: Data from Danish inpatients and outpatients. Acta Derm Venereol. 2000;272–6.
10.
Reich K, Segaert S, Van De Kerkhof P, Durian C, Boussuge M, Paolozzi L, et al. Once-Weekly Administration of Etanercept 50 mg Improves Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis. Dermatology. 2009;(3):239–49.
11.
Reid E, Haley A, Borovicka J, Rademaker A, West D, Colavincenzo M, et al. Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia. J Am Acad Dermatol. 2012;97–102.
12.
Alghamdi K, Alshammari S. Arabic version of Skindex-16: Translation and cultural adaptation, with assessment of reliability and validity. International Journal of Dermatology. 2007;247–52.
13.
Wahl A, Mørk C, Mørk B, Myrdal A, Helland S, Berit R, et al. Changes in quality of life in persons with eczema and psoriasis after treatment in departments of dermatology. Acta Derm Venereol. 2006;(3):198–201.
14.
Ta Luger T, Barker J, Lambert J, Yang S, Robertson D, Foehl J, et al. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. JEADV. 2009;(8):896–904.
15.
Yano C, Saeki H, Ishiji T, Ishiuji Y, Sato J, Tofuku Y, et al. Imact of disease severity on work productivity and activity impairment in Japanese patients with atopic dermatitis. J Dermatol. 2013;(9):736–9.
16.
Finlay A, Coles E. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol. 1995;236–44.
17.
Balkrishnan R, Mcmichael A, Camacho F, Saltzberg F, Housman T, Grummer S, et al. Development and validation of a health-related quality of life instrument for women with melasma. Br J Dermatol. 2003;(3):572–7.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
